In Indonesia, with a population of over 270 million people, the infectious nature of the corona virus is of particular concern. To combat the pandemic, there is a need for technological innovations that can help to make a difference.
The Faculty of Medicine at Universitas Indonesia, in collaboration with Dr. Cipto Mangunkusumo National General Hospital, have partnered with us to validate the CAD4COVID software.
Both organisations are also supporting the validation of CAD4TB, which has already been used to screen for tuberculosis across prisons in Jakarta; a project for which an MoU was signed last March between the Ministry of Health in Indonesia, Delft Imaging and its local partner IDBH Senso.
The Faculty of Medicine at Universitas Indonesia and Dr. Cipto Mangunkusumo National General Hospital have worked out a two-phased validation study to validate the performance of the CAD4COVID software, as well as its potential use case to combat COVID-19 in Indonesia.
The first phase of the validation study has recently been completed, after which the organisations have concluded: “The initial utilization of the AI toolbox at our hospital demonstrates that CAD4COVID has the potential to be implemented as a screening tool to detect suspected individuals of COVID-19 as it exhibits potential correlation with RT-PCR result. We recommend its usage in a resource-constrained environment.”